Literature DB >> 9001360

Mitochondrial NADH- or NADPH-linked aquacobalamin reductase activity is low in human skin fibroblasts with defects in synthesis of cobalamin coenzymes.

F Watanabe1, H Saido, R Yamaji, K Miyatake, Y Isegawa, A Ito, T Yubisui, D S Rosenblatt, Y Nakano.   

Abstract

Mammalian livers have been reported to contain NADH- and NADPH-linked aquacobalamin reductases, which are distributed in both mitochondria and microsomes. The four aquacobalamin reductase isozymes have been purified and characterized from rat liver. It is unclear which aquacobalamin reductase among the four reductase isozymes participates in the synthesis of cobalamin coenzymes. To clarify the physiological roles of the aquacobalamin reductase isozymes, human mutant fibroblasts (cblC and cblA cells) with defects in cobalamin reductases involved in the coenzyme synthesis were used. In the cblC cells, the activity of the mitochondrial NADH-linked aquacobalamin reductase was reduced significantly, compared with normal human fibroblasts but the mitochondrial NADPH-linked enzyme was not. The reduced specific activity of the NADH-linked enzyme was not due to reduction in levels of the enzyme, but in its affinity for NADH. Although there was not a significant difference in the mitochondrial NADH-linked enzyme activity between normal and cblA cells, the activity of the mitochondrial NADPH-linked enzyme was not detectable in the mutant cells. These results indicate that the defects in the mitochondrial NADH- and NADPH-linked aquacobalamin reductases underlie cblC and cblA disorders, respectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9001360     DOI: 10.1093/jn/126.12.2947

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  8 in total

1.  Structure of ATP-bound human ATP:cobalamin adenosyltransferase.

Authors:  Heidi L Schubert; Christopher P Hill
Journal:  Biochemistry       Date:  2006-12-26       Impact factor: 3.162

2.  Vitamin B12 protects against superoxide-induced cell injury in human aortic endothelial cells.

Authors:  Edward S Moreira; Nicola E Brasch; June Yun
Journal:  Free Radic Biol Med       Date:  2011-06-02       Impact factor: 7.376

3.  Catalytic effect of riboflavin on electron transfer from NADH to aquacobalamin.

Authors:  Ilia A Dereven'kov; Luciana Hannibal; Sergei V Makarov; Pavel A Molodtsov
Journal:  J Biol Inorg Chem       Date:  2019-11-26       Impact factor: 3.358

4.  Mechanistic Studies on the Reaction of Nitrocobalamin with Glutathione: Kinetic evidence for formation of an aquacobalamin intermediate.

Authors:  David T Walker; Rohan S Dassanayake; Kamille A Garcia; Riya Mukherjee; Nicola E Brasch
Journal:  Eur J Inorg Chem       Date:  2013-06-01       Impact factor: 2.524

5.  Progressive neurological deterioration and MRI changes in cblC methylmalonic acidaemia treated with hydroxocobalamin.

Authors:  G M Enns; A J Barkovich; D S Rosenblatt; D R Fredrick; K Weisiger; C Ohnstad; S Packman
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

6.  Identification of the gene responsible for the cblA complementation group of vitamin B12-responsive methylmalonic acidemia based on analysis of prokaryotic gene arrangements.

Authors:  C Melissa Dobson; Timothy Wai; Daniel Leclerc; Aaron Wilson; Xuchu Wu; Carole Doré; Thomas Hudson; David S Rosenblatt; Roy A Gravel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-15       Impact factor: 11.205

7.  Complementation studies in the cblA class of inborn error of cobalamin metabolism: evidence for interallelic complementation and for a new complementation class (cblH).

Authors:  D Watkins; N Matiaszuk; D S Rosenblatt
Journal:  J Med Genet       Date:  2000-07       Impact factor: 6.318

8.  ESR1 Regulates the Obesity- and Metabolism-Differential Gene MMAA to Inhibit the Occurrence and Development of Hepatocellular Carcinoma.

Authors:  Yiyin Zhang; Jiaxi Cheng; Cheng Zhong; Qiming Xia; Yirun Li; Peng Chen; Xiaoxiao Fan; Qijiang Mao; Hui Lin; Defei Hong
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.